Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease
|ClinicalTrials.gov Identifier: NCT01196871|
Recruitment Status : Completed
First Posted : September 9, 2010
Last Update Posted : January 27, 2014
Information provided by (Responsible Party):
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
|Recruitment Status :||Completed|
|Primary Completion Date :||June 2012|
|Study Completion Date :||October 2012|
|Certification/Extension First Submitted :||July 18, 2013|
|Submission Cycle||Results Submitted to ClinicalTrials.gov||Results Returned after Quality Control Review|
|1||January 9, 2018||February 14, 2018|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Warnock DG, Bichet DG, Holida M, Goker-Alpan O, Nicholls K, Thomas M, Eyskens F, Shankar S, Adera M, Sitaraman S, Khanna R, Flanagan JJ, Wustman BA, Barth J, Barlow C, Valenzano KJ, Lockhart DJ, Boudes P, Johnson FK. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. PLoS One. 2015 Aug 7;10(8):e0134341. doi: 10.1371/journal.pone.0134341. eCollection 2015.